REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/06/2026
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Quick snapshot
DELIVEREX
ST13
US500000079282940Class
Filing
Registration
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Case type
Recorded events
Latest update
Classification
Trademark type
Nice classes
Filing date
Registration date
Expiration date
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Structured fields from the responsible authority and the official record.
Status date
Last transaction
Responsible office
Status code
Official register
Drawing code
Owner type
Owner location
Examiner
Law office
Current location
Holders
Representatives
Bryce J. Maynard Buchanan Ingersoll & Rooney PC
Nice Classes
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy
Class 44
Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy
History of USPTO decisions and trademark events.
37 publications found
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/06/2026
NEW REPRESENTATIVE AT IB RECEIVED
12/04/2021
FINAL DECISION TRANSACTION PROCESSED BY IB
11/23/2021
FINAL DISPOSITION NOTICE SENT TO IB
11/01/2021
FINAL DISPOSITION PROCESSED
11/01/2021
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/06/2021
REGISTERED-PRINCIPAL REGISTER
07/06/2021
LIMITATION FROM THE IB EXAMINED AND ENTERED
05/04/2021
LIMITATION OF GOODS RECEIVED FROM IB
05/01/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/20/2021
PUBLISHED FOR OPPOSITION
04/20/2021
NOTIFICATION PROCESSED BY IB
04/18/2021
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/31/2021
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/31/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/31/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
03/13/2021
EXAMINER'S AMENDMENT ENTERED
03/13/2021
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/13/2021
EXAMINERS AMENDMENT E-MAILED
03/13/2021
EXAMINERS AMENDMENT -WRITTEN
03/13/2021
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/06/2021
LETTER OF SUSPENSION E-MAILED
03/06/2021
SUSPENSION LETTER WRITTEN
03/06/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
01/28/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/28/2021
ASSIGNED TO LIE
01/27/2021
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/16/2020
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2020
REFUSAL PROCESSED BY IB
05/29/2020
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/14/2020
REFUSAL PROCESSED BY MPU
05/14/2020
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/30/2020
NON-FINAL ACTION WRITTEN
04/29/2020
ASSIGNED TO EXAMINER
04/20/2020
APPLICATION FILING RECEIPT MAILED
04/17/2020
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/13/2020
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/09/2020
Continuous trademark protection
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.